buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. a mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence.in this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of b...

Buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. A mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence.In this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of b...

Buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. A mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence.In this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of b...

Buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. A mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence. In this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of ...

buprenorphine (subutex) has been used to treat opioid dependency in the past 16 years. subutex (or buprenorphine hydrochloride) was approved by the singapore's ministry of health (moh) in 2000 as a substitution treatment for opiate-dependent drug abusers within the framework of medical, social and psychological treatments. it was subsequently introduced into the singapore market in 2002. i...

CONTEXT The prevalence of heroin and other opioid use has markedly increased among adolescents in the last decade; however, virtually no research has been conducted to identify effective treatments for this population. OBJECTIVE To evaluate the relative efficacy of 2 pharmacotherapies, the partial opioid agonist buprenorphine hydrochloride and the centrally active alpha(2)-adrenergic blocker ...

The Drug Addiction Treatment Act of 2000 (DATA 2000) was established to create a new paradigm for medication-assisted treatment of persons with opiate addiction in the United States. Before enactment of DATA 2000, the use of opioid medications to treat patients with opioid addiction was permissible only in federally approved treatment programs, ie, "methadone clinics." The only medications perm...

A reverse phase high performance liquid chromatographic (RPHPLC) method has been developed and validated for simultaneous estimation of Naloxone Hydrochloride and Buprenorphine Hydrochloride in pure and marketed formulations. Separation was carried out using column Hypersil ODS C18 (250 mm x 4.6mm x 5μm particle size) in isocratic mode using mobile phase composition pH 6.0 ammonium acetate Buff...

BACKGROUND Levomethadyl acetate, methadone hydrochloride, and buprenorphine hydrochloride are equally effective treatments for opioid dependence. Each blocks the human ether-a-go-go-related gene (hERG)-associated channel in vitro and represents a risk for QT prolongation. To compare the effects of 3 known hERG-associated channel blockers on the corrected QT (QTc), we conducted a randomized, con...

BACKGROUND Federal initiatives aim to increase office-based treatment of opioid dependence, but, to our knowledge, factors associated with willingness to deliver this care have not been defined. The objective of this study was to describe clinics' willingness to provide methadone hydrochloride or buprenorphine hydrochloride for opioid dependence. METHODS The design of the study was a survey c...